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1. Introduction 
Drug discovery and development process aims to make available new pharmacological 
interventions to prevent, treat, mitigate, or cure disease in a safe and effective manner. It is a 
slow, complex, multi disciplinary and costly process. Drug development starts with a target 
identification and validation, followed by drug candidates (hits) discovery, and lead drug 
(compound with favorable pharmaceutical, safety, efficacy, and pharmacokinetic profile) 
selection and optimization. Preclinical (non clinical) efficacy, pharmacology, toxicology, and 
mechanistic studies may include in silico (computational) methods, use of in vitro animal or 
human tissues (including cells and subcellular fractions), and in vivo animals. The studies 
rely on models that are thought to be predictive of the subsequent preclinical or clinical 
effects. Guidances (government-regulated standards of normal expectations) for different 
steps are readily available from the regulatory agencies (http://www.fda.gov/ 
drugs/guidancecomplianceregulatoryinformation/guidances/default.htm). The required 
toxic ology studies must be performed according to the Good Laboratory Practice (GLP) 
guidelines. Medicinal chemistry and pharmaceutics also play a crucial role from the 
beginning of the drug discovery and development process, involving chemical synthesis 
(including compliance with current Good Manufacturing Practice, cGMP), characterization, 
purification, chemical alteration, stability determination, and formulation of the drug 
candidate. The first-in-human (FIH) doses are based on the No-Observed-Adverse-Event-
Level (NOAEL) values obtained in the relevant and more sensitive toxicology specie (rodent 
and non-rodent, commonly rat and dog), interspecies dose extrapolation, and a selection of 
an appropriate safety factor. Subsequent to preclinical evaluation, an Investigational New 
Drug (IND) application is submitted to the regulatory agency (e.g. United States Food and 
Drug Administration, FDA or European Medicine Agency, EMEA) summarizing all 
preclinical data (chemical, pharmaceutical, efficacy, toxicology and other) along with a 
rationale for the proposed clinical study and a clinical study protocol. Clinical drug 
development can commence after review of the IND by the regulatory agency and a clinical 
study approval by a local Institutional Review Board (IRB, a committee of scientists and 
non-scientists overseeing the clinical research). Phase 1 studies commonly use human 
volunteers to determine human safety and pharmacokinetics. Frequently, these studies also 
include biomarkers of efficacy as secondary endpoints. Drugs with acceptable safety profiles 
then enter Phase 2 for efficacy evaluations. These include the proof-of-principle studies to 
demonstrate effects on disease-relevant biomarkers and the proof-of-concept studies to 
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demonstrate direct effects on the target disease in a small patient sampling. Controlled trials 
are commonly designed to compare effects of the new drug to a placebo or to a standard of 
care treatment (for ethical reasons). Drugs showing promising efficacy continue to Phase 3, 
much larger trials examining efficacy as well as safety. Drugs emerging from these trials 
with appropriate evidence of safety and efficacy are submitted for marketing approval via a 
New Drug Application (NDA). Following a review and approval by the regulatory agency, 
the drug can then be marketed and enters Phase 4 or post-marketing monitoring.  
Recent estimates suggest that it takes up to 13.5 years and 1.8 billion U.S. dollars to bring a 
new drug to the market [17]. There are rising concerns over the diminished productivity 
(number of new medical entities approved) in face of the escalating cost (R&D spending). In 
view of this, there is a growing effort and urgency to find new approaches aiming to 
decrease attrition and increase success in drug development [8, 10, 11, 17]. This is at times 
when number of drug blockbusters is coming off patent, large personnel layoffs and 
pharmaceutical consolidation (buying and merging in an effort to shore up pharmaceutical 
company pipelines). There are strong beliefs that pharmaceutical industry needs to find 
means of improving efficiency and effectiveness in order to sustain itself. Two independent 
studies, one by the FDA and the other by the European Federation of Pharmaceutical 
Industries and Associations (EFPIA), examined the causes behind the decreasing 
productivity. Based on these studies, improvements in predictivity of safety and efficacy 
were deemed to have the greatest potential for reversing the trend of diminished 
productivity and success [10]. This led to formation of public-private initiatives aiming to 
accelerate the development of better and safer medicines, the Innovative Medicines 
Initiative, IMI (http://imi.europa.eu) and the Critical Path Institute, C-PATH 
(http://www.c-path.org/). In 2004, FDA launched the Critical Path Initiative (CPI) as 
described in its white paper Innovation/Stagnation: Challenge and Opportunity on the Critical 
Path to New Medical Products (http://www.fda.gov/ScienceResearch/SpecialTopics/Critical 
PathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm):  
“Sounding the alarm on the increasing difficulty and unpredictability of medical product 
development, the report concluded that collective action was needed to modernize scientific and 
technical tools as well as harness information technology to evaluate and predict the safety, 
effectiveness, and manufacturability of medical products. The report called for a national effort to 
identify specific activities all along the critical path of medical product development and use, which, if 
undertaken, would help transform the critical path sciences.”  
This was echoed in subsequent C-PATH reports (http://www.fda.gov/ 
downloads/ScienceResearch/SpecialTopics/CriticalPathInitiative/UCM186110.pdf;http://
www.fda.gov/ScienceResearch/SpecialTopics/CriticalPathInitiative/ucm076689.htm). Dr. 
Raymond Woosley, the president and CEO of the C-PATH is quoted on the C-PATH’s 
website that it presently takes 15 years for drug development and 95% of drug candidate fail 
along the way. The very ambitious goal cited by the Institute is to shorten the time to 3 years 
and improve the success to 95%.  
Major reasons cited for drug attrition are lack of efficacy, presence of toxicity, and 
commercial concerns [12]. It was reported that only 5% of the compounds entering the first-
in-human studies in oncology achieve successful registration [12]. Majority of failures 
occurred in Phase 3 and were attributed to the lack of efficacy proof of concept, lack of 
objective and robust biomarkers, inadequate predictivity and poor translation of scientific 
discoveries and preclinical information to clinical settings. Innovation was commonly 
www.intechopen.com
 
Overview of Current Drug Discovery and Development with an Eye Towards the Future 
 
3 
viewed as one of the most needed approaches to reversing the situation [8, 11, 17, 24]. A 
recent Science editorial by the current FDA commissioner [6] echoed these viewpoints. 
Commonly cited areas for potential and fruitful innovations include the development 
process itself, identification, validation and qualification of relevant biomarkers, predictive 
modeling, clinical trial subject selection, clinical trial design, and collaborative efforts 
involving pharmaceutical companies, academia, government, and public.  
“Fail fast, fail cheap” is a common mantra in the pharmaceutical industry. This is intended 
to minimize losses of time, resources, and expenses. There are number of go/no-go decision 
gates along the common drug development path. Earlier an appropriate no-go decision is 
made, lesser the possibility for waste. Drug developers strive to identify the most effective 
and efficient means of bringing safe and effective products to the market. Success along the 
development path hinges on using appropriate and robust models and biomarkers, which 
are relevant and predictive of a disease process of interest. One frequently proposed 
solution is to move the clinical proof-of-concept phase to an earlier point on the drug 
development timeline and in a bidirectional manner with the preclinical development [17]. 
It’s expected that this would result in a lesser number of drug candidates entering later 
clinical testing phases but with increasing probability of their success. 
In an effort to decrease the development time and improve drug development efficiency, the 
regulatory agencies have recently introduced the Exploratory Phase (also known as Phase 0) 
option(http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformati
on/Guidances/ucm078933.pdf). The regu latory requirements for Exploratory Phase are 
lesser than those for Phase 1 but the doses and scope of the former are also more limited. 
The Exploratory Phase has no therapeutic or diagnostic intent. Its purpose is to obtain 
pharmacokinetic and/or pharmacodynamic data and thereby provide an opportunity to 
obtain the necessary information for an early decision whether to continue the development 
or to select the optimum candidate or formulation for development [22].  
One of the major initiatives in an effort to improve the efficiency and success in drug 
development deals with identification and validation of robust and predictive biomarkers. 
Biomarkers play a pivotal role throughout the drug discovery and development process, 
from the beginning through post-marketing. Biomarker Consortium, composed of the 
National Institutes of Health, the FDA, the Center for Medicare and Medicaid Services, 
Pharmaceutical Research and Manufacturers of America (PhRMA), Biotechnology Industry 
Association (BIO), pharmaceutical companies, academia, and patient groups, was formed in 
the United States to accelerate development in this area. Present and future perspectives by 
FDA on molecular biomarkers have been summarized in a recent publication [7]. The 
Predictive Safety Testing Consortium, PSTC (http://www.c-path.org/pstc.cfm ) represents 
an example of one successful collaborative effort stemming from some of these initiatives. In 
collaboration with the regulatory agencies (FDA and EMEA), the PSTC worked on defining 
methodologies and validations for new safety biomarkers and presented an initial path and 
outline for regulatory qualification of biomarkers [5, 21]). In addition through the efforts of 
the Nephrotoxicity Working Group, seven renal biomarkers have been qualified for limited 
use in nonclinical and clinical drug development as a measure of drug safety. These efforts 
were highlighted in a special issue of Nature Biotechnology (http://www.natur 
e.com/nbt/journal/v28/n5/index.html ).  
Advances in hardware and software computational power and sophistication are fueling the 
rapidly growing reliance on computers and computational modeling in an attempt to 
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improve the efficiency and effectiveness in the drug discovery and development process [9]. 
It’s not uncommon to hear statements at drug development conferences that computational 
modeling will play the major role in drug design and development in not too distant future, 
similar to its role presently in the automotive and airplane industries. Computational 
modeling addresses the key critical element in all aspects of the drug discovery and 
development process, the prediction [13]. This in silico approach is thought to obviate some 
disadvantages of the more traditional approaches (need for large amounts of test agent for 
in vivo testing, poor predictability of in vivo animal and in vitro models for human toxicity 
and efficacy, lack of reliable high-throughput in vitro assays and a lack of animal models for 
some common adverse events seen in humans, e.g. headache, nausea, dizziness) [16]. There 
are also increasing legal requirements, especially in Europe, for use of alternative, non-
animal models in the regulatory safety assessment of chemicals and urging development, 
independent assessment and application of computational methods. [15]. As stated in the 
Science editorial: “The FDA is also working to eventually replace animal testing with a 
combination of in silico and in vitro approaches” [6]. In 2007, the National Academy of 
Sciences also proposed a shift away from the current animal toxicology testing to use of 
emerging technologies i.e., in vitro assays using human cells, non-mammalian model 
organisms, high throughput testing, imaging technologies, omics technologies, systems 
biology, and computational modeling. Some of the advantages and disadvantages of these 
approaches were recently discussed by van Vliet [23]. In order to address the great 
complexity of the biological systems, extensive computational power is required and there 
are several major virtual screening efforts utilizing grid or distributed computing (e.g. 
http://www.worldcommunitygrid.org/research/hdc/overview.do). PriceWaterhouse 
Coopers  Pharma 2005: An Industrial Revolution in R&D report emphasized the growth and 
value of in silico approaches and projected that in silico methods will become dominant from 
drug discovery through marketing (http://www.pwc.com/en_GX/gx/pharma-
lifesciences/pdf/industrial_revolution.pdf). Furthermore, the report suggested that we are 
in a transitional period where the roles of primary (laboratory and clinical studies) and 
secondary (computational) science are in process of reversal. In a more recent report, 
PriceWaterhouseCoopers Pharma 2020: Virtual R&D, it was stated that pharmaceutical 
innovation and productivity could be improved significantly via enhanced and more 
complete molecular understanding of the human body and a more complete knowledge of 
human disease pathophysiology, thereby enabling development of more predictive 
computational models (http://www.pwc.be/en/pharma/pdf/Pharma-2020-virtual-rd-
PwC-09.pdf). This was envisioned as a path towards predictive biosimulation in form of a 
“virtual man” and a “virtual patient” in some not too distant future with some of the effort 
along these lines already in progress.  
The rapid growth in scientific knowledge and computational capabilities is also providing 
means for integrating and analyzing disparate chemical, biochemical, physiological, 
pathological, and clinical data in a parallel as opposed to a sequential fashion. Systems 
biology applies principles and mathematical tools of electrical engineering and networks to 
dynamic modeling and simulation of complex biological systems in a holistic manner. This 
is facilitating a change in drug discovery and development paradigm away from the 
reductionist approach. It’s becoming more recognized that a commonly utilized reductionist 
approach may not be well suited for complex human disease processes and that the old 
magic bullet paradigm needs to be replaced by a magic shotgun for many of the diseases 
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[19]. Human physiology and pathology are very complex involving multi-factorial and 
heterogenous processes with dynamic, redundant and interactive networks and signaling 
pathways [1-4, 14, 18, 20]. In fact, the term “Network Medicine” and what it entails is 
growing in recognition [2]. Furthermore, one size doesn’t fit all and the targets may also 
change as the disease progresses. In many cases, it’s more relevant to understand the system 
and how to apply and interpret its perturbations in order to achieve desired efficacy and 
safety as opposed to concentrating on a single target. In fact, a partial modification of several 
targets may be more effective and safer than a complete modification of a single target.  
Based on the above overview, it is clear that changes and innovations in drug discovery and 
development are needed and that there are ongoing efforts in this area on several fronts. 
Ultimately, the success hinges on improving the predictivity of efficacy and toxicity, which 
in turn depends on innovations and having reliable and robust biomarkers and using 
appropriate tools and methodologies.  
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